A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions
View abstract on PubMed
Summary
This summary is machine-generated.Repeat carboplatin skin testing (ST) is crucial for patients with a history of hypersensitivity reactions (HSRs) who initially test negative. This strategy identifies patients at higher risk for future reactions during desensitization, improving safety.
Area Of Science
- Oncology
- Clinical Immunology
- Pharmacology
Background
- Carboplatin hypersensitivity reactions (HSRs) pose management challenges due to unreliable initial skin test (ST) results.
- Patients with a history of carboplatin HSR and negative ST results may remain at risk for subsequent reactions.
- A novel protocol involving repeat skin testing and desensitization is proposed to enhance risk stratification.
Purpose Of The Study
- To identify an effective management strategy for patients with a history of carboplatin-induced HSRs who have negative carboplatin skin test results.
- To improve the accuracy of risk stratification for patients undergoing carboplatin treatment after experiencing HSRs.
Main Methods
- A protocol was implemented from 2008-2010 for patients with carboplatin-induced HSRs.
- Risk stratification involved up to three repeat skin tests (STs) with intervening drug desensitization procedures.
- Patient outcomes were monitored based on ST results (positive, negative, or converter).
Main Results
- Of 44 patients, 39 completed the protocol, with 16 testing positive, 11 remaining negative, and 12 converting from negative to positive ST results.
- ST converters demonstrated a significantly higher incidence of HSRs during desensitization (56.1%) compared to persistently negative ST patients (4.5%).
- ST converters had a longer interval between initial HSR and ST evaluation than both positive and true-negative ST groups.
Conclusions
- Repeat skin testing is essential for accurate risk stratification in patients with a history of carboplatin HSR and an initial negative ST result.
- A significant rate of conversion to positive ST results highlights the need for repeated testing.
- ST converters face an elevated risk of HSRs during subsequent carboplatin desensitization and treatment.